Diabetes Care, Vol 23, Issue 8 1072-1078, Copyright © 2000 by American Diabetes Association

ARTICLES

Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry

K Decochez, B Keymeulen, G Somers, H Dorchy, IH De Leeuw, C Mathieu, R Rottiers, F Winnock, K ver Elst, I Weets, L Kaufman, DG Pipeleers and R Rottiers
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.

OBJECTIVE: To investigate whether the presence of antibody markers at diagnosis could help predict the rapid decrease in residual beta-cell function noted in some, but not all, patients with recent-onset type 1 diabetes. RESEARCH DESIGN AND METHODS: We measured random C-peptide levels (radioimmunoassay); islet cell cytoplasmic antibodies (ICA) (indirect immunofluorescence); and antibodies against IA-2 protein, 65-kDa glutamate decarboxylase, and insulin (liquid-phase radiobinding assays) in 172 patients <40 years of age with type 1 diabetes. The patients had been consecutively recruited at diagnosis by the Belgian Diabetes Registry and were followed for 2 years. RESULTS: Two years after diagnosis, random C-peptide levels had decreased significantly (P < 0.001) in ICA+ patients but not in ICA- patients. C-peptide values <50 pmol/ were noted in 88% of patients diagnosed before 7 years of age, in 45% of patients diagnosed between ages 7 and 15 years, and in 29% of patients diagnosed after 15 years of age (P < 0.001). In cases of clinical onset before age 15 years, a rapid decline in random C-peptide values was observed almost exclusively in patients with high-titer ICA (> or =50 Juvenile Diabetes Foundation [JDF] units) at diagnosis (69 vs. 17% in patients with lower ICA titers, P < 0.001). In patients diagnosed after 15 years of age, 36% of patients with ICA titers > or =12JDF units developed low C-peptide levels compared with 14% of patients with ICA titers < 12 JDF units (P < 0.03). Multivariate analysis confirmed that C-peptide levels after 2 years were inversely correlated with ICA levels (P < 0.001) and to a lesser degree positively correlated with age at diagnosis (P < 0.02), regardless of the levels or number of molecular autoantibodies. CONCLUSIONS: Young age at diagnosis and high-titer ICA identify a group of type 1 diabetic patients at high risk of rapidly losing residual beta-cell function. Using these selection criteria, it is possible to better target beta-cell-preserving interventions to patients with or without such rapid progression, depending on the nature of the tested substance. The ICA assay measures clinically relevant antibodies not detected in antibody assays that use recombinant human autoantigens for substrate.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]

				B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes N. Engl. J. Med., June 23, 2005; 352(25): 2598 - 2608. [Abstract] [Full Text] [PDF]

				G. Bruno, F. Cerutti, F. Merletti, P. Cavallo-Perin, E. Gandolfo, M. Rivetti, C. Runzo, S. Pinach, G. Pagano, and The Piedmont Study Group for Diabetes Epidemiology Residual {beta}-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in Children: The registry of type 1 diabetes of the province of Turin, Italy, 1984-2000 Diabetes Care, February 1, 2005; 28(2): 312 - 317. [Abstract] [Full Text] [PDF]

				E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]

				C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				P. Hanifi-Moghaddam, N. C. Schloot, S. Kappler, J. Seissler, and H. Kolb An Association of Autoantibody Status and Serum Cytokine Levels in Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1137 - 1142. [Abstract] [Full Text] [PDF]

				S. K. Bhowmick, B. Estrada, and K. R. Rettig Insulin-Dependent Diabetes Mellitus in 2 Male African American Children After Kawasaki Disease Pediatrics, August 1, 2002; 110(2): e27 - 27. [Abstract] [Full Text] [PDF]

				M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin Diabetes Care, July 1, 2002; 25(7): 1192 - 1197. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, P. Fernlund, and G. Sundkvist A 12-Year Prospective Study of the Relationship Between Islet Antibodies and {beta}-Cell Function At and After the Diagnosis in Patients With Adult-Onset Diabetes Diabetes, June 1, 2002; 51(6): 1754 - 1762. [Abstract] [Full Text] [PDF]

				P. Pozzilli and U. Di Mario Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention Diabetes Care, August 1, 2001; 24(8): 1460 - 1467. [Abstract] [Full Text] [PDF]